Improvement of Sjögren's syndrome after two infusions of rituximab (anti‐CD20)

Abstract

Low-dose rituximab infusions were well tolerated without the benefit of steroids. Infusions induced a rapid depletion of B cells in the blood and SG and could improve primary SS. Controlled studies are needed.